Sareum Holdings PLC (GB:SAR)
LSE:SAR
Want to see GB:SAR full AI Analyst Report?
Top Page
Sareum Holdings
(LSE:SAR)
Select Model
Select Model
Rating:47Neutral
Price Target:
22.50 p
▲(50.00% Upside)
Action:Reiterated
Date:06/02/26
The score is held down primarily by weak financial performance (pre-revenue, ongoing losses, and continued cash burn requiring funding). Technicals are supportive with strong trend signals, but overbought momentum tempers the outlook. Valuation is constrained by negative earnings (negative P/E) and no dividend support.
Positive Factors
Debt-free balance sheet
No reported debt materially lowers bankruptcy risk and gives management flexibility when timing licensing deals or fundraising. Over the next several months this structural balance-sheet strength reduces refinancing pressure and enhances counterparty confidence in collaborations.
Negative Factors
Pre-revenue, persistent losses
Being pre-revenue with recurring operating losses means the company cannot self-fund R&D or overhead; profitability is distant and contingent on successful partner deals or clinical progress. This structural earnings weakness increases funding dependency and execution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
No reported debt materially lowers bankruptcy risk and gives management flexibility when timing licensing deals or fundraising. Over the next several months this structural balance-sheet strength reduces refinancing pressure and enhances counterparty confidence in collaborations.
Read all positive factors
Sareum Holdings (SAR) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£29.79M
Dividend YieldN/A
Average Volume (3M)619.72K
Price to Earnings (P/E)―
Beta (1Y)-0.22
Revenue GrowthN/A
EPS Growth-105.65%
CountryUK
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.04
Shares Outstanding138,565,170
10 Day Avg. Volume1,134,615
30 Day Avg. Volume619,716
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)8.68
Price to Sales (P/S)0.00
P/FCF Ratio-7.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)£43.15M
Sareum Holdings Business Overview & Revenue Model
Company Description
Sareum Holdings plc operates as a specialized pharmaceutical company, primarily focused on discovering and advancing innovative therapeutic compounds for treating both cancer and autoimmune conditions. The firm develops small-molecule drugs, utili...
How the Company Makes Money
Sareum’s primary business model is to create value from its drug discovery and early development pipeline and monetize that value through partnering and licensing rather than through direct product sales. Revenue, when generated, typically comes f...
Sareum Holdings Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
52
Neutral
Cash Flow
28
Negative
| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | -1.00K | -1.00K | -2.00K | -1.09K |
| EBITDA | -5.40M | -3.38M | -4.54M | -4.01M | -2.57M | -1.70M |
| Net Income | -4.93M | -4.44M | -3.42M | -3.19M | -2.17M | -1.50M |
Balance Sheet | ||||||
| Total Assets | 3.23M | 4.23M | 2.77M | 2.02M | 4.79M | 3.08M |
| Cash, Cash Equivalents and Short-Term Investments | 2.49M | 3.55M | 1.46M | 994.00K | 4.26M | 2.69M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 2.04M | 1.95M | 653.00K | 867.00K | 455.00K | 284.15K |
| Stockholders Equity | 1.19M | 2.28M | 2.11M | 1.15M | 4.33M | 2.80M |
Cash Flow | ||||||
| Free Cash Flow | -3.25M | -2.55M | -3.92M | -3.27M | -2.13M | -1.57M |
| Operating Cash Flow | -3.25M | -2.55M | -3.92M | -3.27M | -2.13M | -1.57M |
| Investing Cash Flow | 12.00K | 89.00K | 9.00K | -41.00K | -2.00K | -37.86K |
| Financing Cash Flow | 1.58M | 4.55M | 4.38M | 0.00 | 3.71M | 2.49M |
Sareum Holdings Technical Analysis
Positive
15.00
Price Trends
21.23
Positive
18.66
Positive
18.25
Positive
Market Momentum
0.32
Positive
45.43
Neutral
11.40
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:SAR, the sentiment is Positive. The current price of 15 is below the 20-day moving average (MA) of 22.57, below the 50-day MA of 21.23, and below the 200-day MA of 18.25, indicating a neutral trend. The MACD of 0.32 indicates Positive momentum. The RSI at 45.43 is Neutral, neither overbought nor oversold. The STOCH value of 11.40 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:SAR.
Sareum Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | £53.59M | -9.39 | -55.47% | ― | ― | 19.83% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | £29.79M | -6.01 | -284.01% | ― | ― | -105.65% | |
46 Neutral | £23.60M | 35.54 | -197.54% | ― | 3.31% | 21.91% | |
44 Neutral | £15.02M | -9.26 | -210.32% | ― | -11.43% | 23.40% | |
41 Neutral | £27.48M | -7.57 | -1397.43% | ― | ― | 36.67% | |
40 Underperform | £16.41M | -5.08 | -213.66% | ― | 13.42% | 65.63% |
* Healthcare Sector Average
GB:SAR
Sareum Holdings
21.50
7.25
50.88%
GB:IMM
ImmuPharma
4.41
2.09
90.28%
GB:FAB
Fusion Antibodies Plc
12.50
6.20
98.41%
GB:POLB
Poolbeg Pharma Ltd.
7.60
4.95
186.79%
GB:AREC
Arecor Therapeutics PLC
62.50
19.00
43.68%
GB:APTA
Aptamer Group Plc
0.53
0.21
64.06%
Sareum Holdings Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Sareum Adds £62,500 via Warrant Exercise as Share Count Rises
Positive
May 1, 2026
Sareum Holdings has received notice for the exercise of warrants over 500,000 new ordinary shares at 12.5 pence each, raising £62,500 in fresh equity capital. Application has been made for the new shares to be admitted to trading on AIM, wher...
Business Operations and StrategyFinancial Disclosures
Sareum Restarts Key Toxicology Study as TYK2 Pipeline and Partnering Drive Half-Year Progress
Positive
Mar 12, 2026
Sareum Holdings reported half-year results to 31 December 2025, underscoring progress on its pipeline of kinase inhibitors for autoimmune disease, cancer and neuroinflammation, while ending the period with £2.5 million in cash and a reduced p...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.